 <h1>Ingrezza Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>valbenazine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about valbenazine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ingrezza.</p><h2>In Summary</h2><p><b>Common side effects of Ingrezza include:</b> drowsiness, fatigue, and sedated state.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to valbenazine: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, valbenazine (the active ingredient contained in Ingrezza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking valbenazine:</p><p>
<i>Less common</i>
</p><ul>
<li>Absence of or decrease in body movement</li>
<li>clumsiness or unsteadiness</li>
<li>dizziness</li>
<li>drooling</li>
<li>inability to sit still</li>
<li>loss of balance control</li>
<li>need to keep moving</li>
<li>restlessness</li>
<li>trembling and shaking of the fingers or hands</li>
<li>trouble walking</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Fainting</li>
<li>hives or welts, itching, or red skin rash</li>
<li>irregular heartbeat recurrent</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of valbenazine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>decrease in the frequency of urination</li>
<li>decrease in urine volume</li>
<li>difficulty having a bowel movement (stool)</li>
<li>difficulty in passing urine (dribbling)</li>
<li>dry mouth</li>
<li>painful urination</li>
<li>sleepiness or unusual drowsiness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Fear or nervousness</li>
<li>headache</li>
<li>muscle pain or stiffness</li>
<li>nausea</li>
<li>pain in the joints</li>
<li>trouble sleeping</li>
<li>vomiting</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to valbenazine: oral capsule</i></p><h3>General</h3><p>-The most common adverse reaction (5% or more and twice the rate of placebo) was somnolence.</p>
<p>-A total of 3% of patients discontinued treatment because of adverse reactions.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Somnolence/fatigue/sedation (10.9%)</p>
<p><b>Common</b> (1% to 10%): Anticholinergic effects (dry mouth, constipation, attention disturbance, blurred vision, urinary retention), balance disorders/fall/gait disturbance/dizziness, headache, akathisia/restlessness, drooling, dyskinesia, </p>
<p>non-akathisia extrapyramidal symptoms<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Vomiting, nausea<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase and bilirubin<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Increased blood glucose, increased weight, increased prolactin<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory infections<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc., San Diego, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How much does it cost?</li>
<li>What condition is Ingrezza used to treat?</li>
<li>How long does it take for Ingrezza to work?</li>
<li>How effective is Ingrezza?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Ingrezza (valbenazine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: VMAT2 inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ingrezza &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Tardive Dyskinesia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to valbenazine: oral capsule</i></p><h3>General</h3><p>-The most common adverse reaction (5% or more and twice the rate of placebo) was somnolence.</p><p>-A total of 3% of patients discontinued treatment because of adverse reactions.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Somnolence/fatigue/sedation (10.9%)</p><p><b>Common</b> (1% to 10%): Anticholinergic effects (dry mouth, constipation, attention disturbance, blurred vision, urinary retention), balance disorders/fall/gait disturbance/dizziness, headache, akathisia/restlessness, drooling, dyskinesia, </p><p>non-akathisia extrapyramidal symptoms<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Vomiting, nausea<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase and bilirubin<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Increased blood glucose, increased weight, increased prolactin<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory infections<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc., San Diego, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How much does it cost?</li>
<li>What condition is Ingrezza used to treat?</li>
<li>How long does it take for Ingrezza to work?</li>
<li>How effective is Ingrezza?</li>
</ul><h2>More about Ingrezza (valbenazine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: VMAT2 inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ingrezza &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Tardive Dyskinesia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>